

Pulse Pressure in Diabetic Microalbuminuric Adults: An Observation from a Single Centre in Eastern India

Hariballav Mahapatra^{1,4}, Rajesh Kumar Padhi^{1,2,3}, Abhay Sahoo⁴ and Monalisa Khuntia¹

¹Sevayan Diabetes Centre, India

²KIIT University, India

³Kalinga Hospital, India

⁴Siksha O Anusandhan University, India

The prevalence of diabetes and diabetic complications are increasing exponentially day by day. People developing one type of diabetic complication are prone to develop another type of diabetic complication as the basic pathophysiological mechanisms behind their development remain the same. We aimed to study the pattern of pulse pressure and its associated factors among type 2 diabetic subjects with microalbuminuria. The study was conducted at a specialized diabetes care facility in Eastern India involving 260 microalbuminuric diabetic adults aged between 18 to 70 years. Our findings showed a higher prevalence of wide pulse pressure in 84% of the participants. It suggested that wider pulse pressure was associated with male gender, elder participants and those with elevated HbA1c. Subjects in the upper half of microalbuminuria chart exhibited wider pulse pressure than those in the lower microalbuminuric range. No significant correlation was found between pulse pressure and fasting blood in this study.

BACKGROUND & AIM:-

Diabetes has become a global health issue and the number is expected to rise further in the years to come^{1,2}. It is a chronic health condition where the level of glucose in the circulation remains persistently high above an amount that has been permitted and this makes diabetes more of a vascular disorder. It is the most common cause of end stage renal disease^{3,4}, reversible cause of blindness^{5,6} and the second most common cause of below knee amputation. Diabetic patients are at higher risk of developing cardiovascular disease⁷ and coronary artery disease is the main reason of premature death in diabetics⁸. Hypertension and dyslipidemia are the usual companions of hyperglycemia and obesity⁹. Cardiovascular disease, cerebrovascular disease and peripheral arterial diseases are the macrovascular complications of diabetes¹⁰. Similarly complications like diabetic neuropathy, nephropathy and retinopathy are the three microvascular complications that pose significant burden on the individual as well as on the health care system¹¹. The deteriorative effects of hyperglycemia are modulated by several mechanisms including endothelial dysfunction, atherosclerosis, platelet aggregation and oxidative stress^{12,13} leading to accelerated vascular ageing¹⁴. The existence of one type of diabetic complication invites another type of complication due to the common pathophysiological mechanisms¹⁵. Presence of microvascular complications in diabetes multiplies risk of having CV mortality and morbidity^{16, 17}. Renal damage can be seen in a higher proportion of long standing diabetics. Microalbuminuria is one of the earliest indicators of diabetic nephropathy and has prognostic implications from renal point of view¹⁸. In addition to diabetes, kidney disease, hypertension and dyslipidemia, there are several other non-modifiable causes of CV diseases like age, race and gender^{19,20}. Pulse pressure is considered to be one of the easiest means to access the vasculature stiffness status of an individual^{21,22}. Widened pulse pressure is a risk factor for cardiovascular diseases²³.

Pulse pressure is calculated by deducting the diastolic blood pressure from the systolic blood pressure and is expressed in millimeter of mercury²⁴. As pulse pressure is a function of systolic and diastolic pressure, conditions that can influence either of them can change pulse pressure. So the above listed situations have the potential to alter the vascular endothelium and finally the pulse pressure of a person²⁵. Pulse pressure increases gradually with age till the 6th decade after which it slowly starts to decline²⁶. Nevertheless microalbuminuria is a potential risk factor for microvascular complication²⁷; pulse pressure is a sign of impending macrovascular complication. The uniqueness of the renal microvasculature is that the afferent arteriolar resistance is low^{28,29}. With this background, we looked into the pulse pressure profile of patients with type 2 diabetes and microalbuminuria.

METHODOLOGY:-

The study was conducted involving adults having type 2 diabetes who visited Sevayan Diabetes Centre, a diabetes specialty facility in an urban area located 60 kilometers away from Bhubaneswar, the state capital of Odisha. The study period was from November 2019 to March 2020. The participants were older than 18 years, but less than 70 years of age in order to be enrolled. Those with type 1 diabetes, gestational diabetes, type 2 diabetes with pregnancy or lactating mothers were excluded from the study. Subjects with normal renal function as evident by normoalbuminuria and those with macroalbuminuria were also excluded. It was only those with microalbuminuria status who were recruited. Similarly subjects who had a history of any degree of kidney disease, whether acute or chronic were also barred from participation. Patients unwilling to participate were also excluded. Consecutive diabetic patients were asked to give their consent before entry into the study. Anthropometric measurements were taken. Thorough medical and surgical history was recorded. All subjects underwent fasting blood glucose, HbA1c measurement and urine microalbumin testing in early morning samples. After a rest for 5 minutes blood pressure was recorded in the dominant arm in a calm environment with a gap of at least one minute between two successive readings. The average of three BP recordings was taken. HbA1c was estimated as per National Glycohemoglobin Standardization Program recommendation and was measured by the recognized boron affinity method from the venous blood sample. Glucose was estimated by GOD-POD method from the blood collected in the fasting state. Diabetes was defined in accordance with the American Diabetes Association guidelines³⁰ as a fasting glucose concentration of 126 mg/dL or higher, HbA1c 6.5% or higher, or self-reported use of anti-hyperglycemic drugs. Early morning urine sample was used to check the urinary albumin status of the participants and was expressed as mg/g. Urinary albumin creatinine ratio (ACR) ≥ 30 mg/g to < 300 mg/g was used to describe microalbuminuria as per KIDGO classification³¹.

RESULTS:-

A total of two hundred sixty persons met the inclusion criteria and were recruited after due consent. The sample included 164 males and 96 females with an average age of 53.3 ± 18.2 years. The mean value for fasting plasma glucose was 157.8 ± 34.7 mg/dl whereas the mean HbA1c was found to be 8.3 ± 2.4 %. The quantitative albumin level in the urine samples averaged at 148.4 ± 67.1 mg/g. The mean systolic and diastolic blood pressure recorded were 156.1 ± 16.2 mm Hg and 89.5 ± 9.7 mm Hg respectively; whereas the mean pulse pressure was 69.3 ± 11.1 mm of Hg. Majority of the study sample exhibited higher pulse pressure. Only 41 subjects had a normal pulse pressure, whereas 219 (84.2%) had an elevated pulse pressure of >60 mm of Hg.

		n =	%
Gender	Males	164	63.1
	Females	96	36.9
Marital status	Married	224	86.2
	Single / widow	36	13.8
BMI	<18.5	11	4.2
	18.5 to <23	173	66.6
	≥ 23	76	29.2
Education	No formal education	9	3.5
	Up to graduation	204	78.5
	Graduation & above	47	18

Table 1

Parameters	Mean \pm SD
Age (years)	53.3 ± 18.2
HbA1c (%)	8.3 ± 2.4
Fasting blood glucose (mg/dl)	157.8 ± 34.7
Microalbuminuria (mg/g)	148.4 ± 67.1

Table 2

When we divided the subjects into two groups based on their pulse pressure, it was seen that the group with higher pulse pressure exhibited more albumin in their urine ($p \leq 0.05$) than the other group. A similar trend of widened pulse pressure was also observed among subjects when they were categorized as per their albuminuria status ($p \leq 0.05$). There was a direct correlation between microalbuminuria and pulse pressure. The higher the level of microalbumin in the urine, greater was the pulse pressure. Both of the above findings were statistically significant and pointed towards a possible and proportionate link between quantity of urinary albumin excretion and pulse pressure.

Variables	Pulse pressure (mm Hg)	p- value	
Gender	Males	73.8 ± 13.4	<0.05
	Females	63.7 ± 10.3	
Age	≤ 55 years	65.1 ± 11.7	<0.05
	> 55 years	73.3 ± 13.2	
Microalbuminuria	Upper half	74.2 ± 13.6	<0.05
	Lower half	64.8 ± 11.2	
HbA1c	$\leq 8.5\%$	65.2 ± 12.4	<0.05
	$>8.5\%$	74.2 ± 11.7	

Table 3

We also found a linear association between HbA1c and pulse pressure. The average pulse pressure of subjects with HbA1c above 8.5% was significantly higher than those whose HbA1c was $\leq 8.5\%$ (65.2 ± 12.4 mm Hg and 74.2 ± 11.7 mm Hg respectively). Three fourth of the subjects with pulse pressure above the upper quadrant of pulse pressure had an HbA1c $\geq 8.5\%$, whereas only 11% of the participants in the lowest quadrant had an HbA1c above 8.5%. On the contrary, no relationship between pulse pressure and short term glycemic control in the form of fasting blood glucose could be drawn ($p < 0.05$). The pulse pressure among the male and female participants varied greatly (73.8 ± 13.4 versus 63.7 ± 10.3 mm Hg) and was statistically significant. Our study found that the younger participants had a lower pulse pressure compared with their elder comparators.

DISCUSSION:-

Microalbuminuria is a powerful predictor of cardiovascular events³³ and may be useful as an early warning sign of diabetic nephropathy³⁴. Hypertension is a common accompaniment in people with diabetes and is linked to end organ damage³⁵. There are cross sectional studies conducted among hypertensive as well as general population showing the association between pulse pressure and microalbuminuria³⁶. The pulse pressure has been linked to morbidity and mortality in people with diabetes, particularly from cardiovascular and renal point of view³⁷. Studies in diabetics show higher pulse pressure³⁸, which was also observed in the present study. Here we found more than 84% of the study participants to be having a hiked pulse pressure. In this study we demonstrated that higher was the microalbuminuria, wider was the pulse pressure. There are several other studies from India which have demonstrated a similar trend of a higher pulse pressure among albuminuric adults³⁹. The gender difference in terms of pulse pressure variation seen in our study could be attributed to the protective effect of estrogen in females and the atherosclerosis promoting effect of testosterone in the males. Ahimastos et al has reported similar findings in their studies which involved pre and post pubertal males and

females⁴⁰. In a meta-analysis, the decrease in eGFR and increase in ACR were associated with an increased risk for cardiovascular mortality independent of each other traditional risk factors⁴¹. Earlier studies have been inconclusive while describing the effects on pulse pressure on renal function, while some showed an increase in pulse pressure on worsening nephropathy^{42,43,44}, while others showed no association between them^{45,46}. We noticed an association between pulse pressure and albumin excretion in the urine. With an increase in the urinary albumin excretion among people with diabetes there as a rise in the pulse pressure as observed in some studies⁴⁷. CKD and CVD are closely associated due to clustering of several cardiovascular risk factors, including hypertension, diabetes mellitus, and dyslipidemia in those patients⁴⁸. We tried to measure blood pressure with accuracy. Single blood pressure reading can potentially overestimate the pulse pressure values⁴⁹. To overcome this we have taken 3 blood pressure readings for each of the participants and considered the average of them. Our study was meant to find a causal relationship between pulse pressure and microalbuminuria in diabetic adults. Moreover this being a cross sectional study, we did not look into the impact of pulse pressure on the progression of diabetic nephropathy. The present study did not segregate the types of antihypertensive medications used by the participants and hence did not evaluate their impact on pulse pressure, which was narrated by some of the investigators in earlier studies⁵⁰. We also did not compare patients based on the presence or absence of diabetic autonomic neuropathy. This was thought to be crucial by some authors as autonomic neuropathy can cause an increase in diastolic blood pressure and hence have the ability to narrow down the pulse pressure⁵¹.

CONCLUSION:-

Our observation concluded that majority of the patients (84%) had high pulse pressure. Data generated from the present study revealed a direct association between pulse pressure and albuminuria among people with diabetes independent of other factors. Wider pulse pressure was found to be linked to male gender and elevated glycated hemoglobin. Our study did not show any relationship between pulse pressure and fasting blood glucose.

REFERENCES:-

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes, estimates for the year 2000 and projections for 2030. *Diabetes Care*. 2004; 27:1047-53.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. *Diabetes Care*. 1998; 21:1414-31.
3. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. *JAMA* 2001;286:421-426.
4. Ekart R, Bevc S, Hojs N, Knehtl M, Dvoršak B, Hojs R: Albuminuria is Associated With Subendocardial Viability Ratio in Chronic Kidney Disease Patients. *Kidney Blood Press Res* 2015;40:565–74.
5. Prevention of Blindness from Diabetic Retinopathy. Report of a WHO Consultation, Geneva November, 2005.
6. Guidelines for the Comprehensive Management of Diabetic Retinopathy in India. A VISION 2020 the Right to Sight India Publication; July, 2008.
7. Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. *Diabetologia*. 2003; 46(6):733-749.
8. Frayn KN Insulin resistance and lipid metabolism. *Curr Opin Lipidol*. 1993; 4:197-204.
9. Sheth J, Shah A, Sheth F, Trivedi S, Nabar N, Shah N et al. The association of dyslipidemia and obesity with glycated hemoglobin. *Clinical Diabetes and Endocrinology*. 2015, 1(1).
10. Wang TJ, Larson MG, Vasan RS, Cheng S, Rhee EP, McCabe E, et al. Metabolite profiles and the risk of developing diabetes. *Nat Med*. 2011; 17(4):448-53.
11. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature*. 2001; 414(6865):813820.
12. Pyörälä KL, Aakso MU, Usitupa M. Diabetes and atherosclerosis: an epidemiologic view. *Diabetes Metab Res Rev*, 1987, 3:463-524.
13. Kreisberg RA Diabetic dyslipidemia. *Am J Cardiol*, 1998, 82:67U-73U.
14. Altered age-related blood pressure pattern in type 1 diabetes. Rönneck M, Fagerudd J, Forsblom C, Pettersson-Fernholm K, Reunanen A, Groop PH, Finnish Diabetic Nephropathy (FinnDiane) Study Group. *Circulation*. 2004 Aug 31; 110(9):1076-82.
15. Goldberg IJ. Diabetic dyslipidemia: causes and consequences. *J Clin Endocrinol Metab*. 2001; 8(3):965- 971.
16. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39:S1.
17. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. *Diabetes Care*. 2004; 27(6):1496-1504.
18. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Hallé JP, Hoogwerf B, Joyce C, Rashkow A, Young J, Zinman B, Yusuf S: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. *Diabetes Care* 2000;23:35–39.
19. Reddy AS, Meera S, William E, Kumar JS. Correlation between glycemic control and lipid profile in type 2 diabetic patients: HbA1c as an indirect indicator of dyslipidemia. *Asian J Pharm Clin Res*. 2014; 7:153- 155.
20. Kayode JA, Adediran OS, Agboola S, Adebisi SA, Idowu A. Lipid profile of type 2 diabetic patients at a rural tertiary hospital in Nigeria. *J Diabetes Endocrinol*. 2010; 1:46-51.
21. Boutouyrie P, Tropeano AI, Asmar R, et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients. *Hypertension*. 2002;39:10–15.
22. Brunet P, Gondouin B, Duval-Sabatier A, Dou L, Cerini C, Dignat-

George F, Jourde-Chiche N, Argiles A, Burtey S: Does uremia cause vascular dysfunction? *Kidney Blood Press Res* 2011;34:284–290.

23. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Boutouyrie P, Tropeano AI, Asmar R, Gautier I, Benetos A, Lacolley P, Laurent S; Hypertension. 2002 Jan; 39(1):10-5.

24. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. *Pediatrics* 2004;114: 555-76.

25. Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting coronary heart disease? The Framingham Heart Study. *Circulation*. 1999; 100:354–360.

26. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Franklin SS, Gustin W 4th, Wong ND, Larson MG, Weber MA, Kannel WB, Levy D; *Circulation*. 1997 Jul 1; 96(1):308-15.

27. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002;39:S1.

28. Loutzenhiser R, Bidani A, Chilton L. Renal myogenic response: kinetic attributes and physiological role. *Circ Res* 2002; 90:1316–1324

29. Ito S, Nagasawa T, Abe M, Mori T. Strain vessel hypothesis: a viewpoint for linkage of albuminuria and cerebro-cardiovascular risk. *Hypertens Res* 2009;32:115–121.

30. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care* 2010;33(Suppl. 1):S62–S69.

31. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. *Kidney Int Suppl*. 2013;3:1–150.

32. (Park SY, Oh HJ, Yoon H: Association of Metabolic syndrome, Metabolic syndrome score and Pulse pressure in Korean Adults: Korea National Health and Nutrition Survey, 2012. *J Korea AcadIndustr Coop Soc* 2014;15:5660–5667.).

33. Dutta D, Choudhuri S, Mondal SA, Mukherjee S, Chowdhury S: Urinary albumin:creatinine ratio predicts prediabetes progression to diabetes and reversal to normoglycemia: role of associated insulin resistance, inflammatory cytokines and low vitamin D. *J Diabetes* 2014; 6: 316–322.

34. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Hallé JB, Hoogwerf B, Joyce C, Rashkow A, Young J, Zinman B, Yusuf S: Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study. The HOPE Study Investigators. *Diabetes Care* 2000; 23: 35–39.

35. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. *BMJ*. 1998;317:703–713.

36. Pedrinelli R, Dell’Omo G, Penno G, et al. Microalbuminuria and

pulse pressure in hypertensive and atherosclerotic men. *Hypertension* 2000;35:48–54 (pmid:10642274), (Cirillo M, Stellato D, Laurenzi M, Panarelli W, Zanchetti A, De Santo NG, The GUBBIO Study Collaborative Research Group . Pulse pressure and isolated systolic hypertension: association with microalbuminuria. *Kidney Int* 2000; 58: 1211–1218

37. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. *Lancet*. 1998;351:1755–1762.

38. Wave reflections and cardiac hypertrophy in chronic uremia. Influence of body size. Marchais SJ, Guerin AP, Pannier BM, Levy BI, Safar ME, London GM *Hypertension*. 1993 Dec; 22(6):876-83.

39. Ardhanari S, Alpert MA, Aggarwal K: Cardiovascular disease in chronic kidney disease: risk factors, pathogenesis, and prevention. *Adv Perit Dial* 2014; 30: 40–53.

40. Ahimastos AA, Formosa M, Dart AM, Kingwell BA. Gender differences in large artery stiffness pre- and post-puberty. *J ClinEndocrinolMetab* 2003;88:5375-80.

41. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van derVelde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT: Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010; 375: 2073-2081.

42. Arulkumaran N, Diwakar R, Tahir Z, Mohamed M, Kaski JC, Banerjee D: Pulse pressure and progression of chronic kidney disease. *J Nephrol* 2010;23:189–193.

43. Arulkumaran N, Diwakar R, Tahir Z, Mohamed M, Kaski JC, Banerjee D: Pulse pressure and progression of chronic kidney disease. *J Nephrol* 2010;23:189–193.

44. Verhave JC, Fesler P, du Cailar G, Ribstein J, Safar ME, Mimran A: Elevated pulse pressure is associated with low renal function in elderly patients with isolated systolic hypertension. *Hypertension* 2005;45:586–591.

45. Nakhjavani M, Nargesi AA, Heidari B, Ghazizadeh Z, Larry M, Esteghamati A: Pulse pressure does not predict the response of diabetic nephropathy to glucose-lowering therapy. *DiabVascDis Res* 2015;12:150–151.

46. Gordin D, Wadén J, Forsblom C, Thorn L, Rosengård-Bärlund M, Tolonen N, Saraheimo M, Harjutsalo V, Groop PH; FinnDiane Study Group: Pulse pressure predicts incident cardiovascular disease but not diabetic nephropathy in patients with type 1 diabetes (The FinnDiane Study). *Diabetes Care* 2011;34:886–891.

47. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, Gansevoort RT, Kasiske BL, Eckardt KU: The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011;80:17–28.

48. Liu M, Li XC, Lu L, Cao Y, Sun RR, Chen S, Zhang PY: Cardiovascular

disease and its relationship with chronic kidney disease. *Eur Rev Med PharmacolSci* 2014; 18: 2918–2926.

49. Birke NJ, Donner AP, Maynard MD. Assessing hypertension control in the community: the need for follow-up measurements to ensure clinical relevance. *Can Med Assoc J.* 1987;136:595–600.

50. Cushman WC, Materson BJ, Williams DW, et al. Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trial. *Hypertension.* 2001;38:953–957.

51. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM complications study. *Diabetologia.* 1996;39:1377–1384.